Clinical Trial Update: MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating MRD-directed donor lymphocyte infusion to reduce relapse after allogeneic hematopoietic stem cell transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
• Minimal Residual Disease in Hematologic Malignancies

Drugs mentioned

• Donor Lymphocyte Infusion

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Minimal Residual Disease, Donor Lymphocyte Infusion | Phase 2, Phase 3 | Status: COMPLETED